RNA干扰药物专利分析

doi:10.5246/jcps.2025.08.052

中国药学(英文版) ›› 2025, Vol. 34 ›› Issue (8): 701-714.DOI: 10.5246/jcps.2025.08.052

• 【综述】 • 下一篇

RNA干扰药物专利分析

李杏^*(), 马璐, 赵亚丽, 张晓霞, 李紫嘉

国家知识产权局专利局专利审查协作天津中心, 天津 300304

收稿日期:2025-02-12 修回日期:2025-03-11 接受日期:2025-03-23 出版日期:2025-08-29 发布日期:2025-08-29
通讯作者: 李杏

Innovative trends in RNA interference drugs: a comprehensive patent analysis

Xing Li^*(), Lu Ma, Yali Zhao, Xiaoxia Zhang, Zijia Li

Patent Examination Cooperation Tianjin Center of the Patent Office, China National Intellectual Property Administration, Tianjin 300304, China

Received:2025-02-12 Revised:2025-03-11 Accepted:2025-03-23 Online:2025-08-29 Published:2025-08-29
Contact: Xing Li

摘要/Abstract

摘要：

核酸药物被誉为开启了继小分子和抗体药物之后的第三代药物研发浪潮, 成为新领域新业态的典型代表之一, 其中RNA干扰(RNAi)药物作为核酸药物研发的热点, 凭借基因沉默效率高､不良反应可控､合成方便等优点, 在慢性病、罕见病等治疗领域得到了广泛应用。本文以RNA干扰药物为例, 针对国内外专利文献进行检索归纳, 系统分析其专利申请趋势、主要申请人、技术构成等方面信息, 同时对该专利领域的关键技术进行具体梳理, 以期为国内医药领域从事RNA干扰药物研究人员提供参考与启示。

关键词: 核酸药物, RNA干扰(RNAi)药物, 小干扰RNA, 专利分析

Abstract:

Nucleic acid drugs represent the third wave of innovation in drug research and development, succeeding small-molecule and antibody drugs. These drugs, particularly RNA interference (RNAi) therapies, have become a pivotal focus in the pharmaceutical industry. RNAi drugs are extensively utilized in the treatment of chronic and rare diseases due to their exceptional gene-silencing efficiency, manageable side effects, and straightforward synthesis process. This study undertook a thorough analysis of the global landscape of RNAi drug patents, highlighting the latest technological advancements and trends. We meticulously identified and cataloged the key technologies that dominated this patent landscape. The goal was to provide valuable insights and references for researchers involved in the development of RNAi drugs within the domestic pharmaceutical sector.

Key words: Nucleic acid drugs, RNA interference (RNAi) drugs, siRNA, Patent analysis

Supporting:

李杏, 马璐, 赵亚丽, 张晓霞, 李紫嘉. RNA干扰药物专利分析[J]. 中国药学(英文版), 2025, 34(8): 701-714.

Xing Li, Lu Ma, Yali Zhao, Xiaoxia Zhang, Zijia Li. Innovative trends in RNA interference drugs: a comprehensive patent analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(8): 701-714.

图/表 8

Figure 1. Global and Chinese trends in siRNA-related patent applications.

Figure 2. Global siRNA-related patent major producers/regions.

Figure 3. Major applicants of global siRNA-related patents.

Figure 4. Major applicants of siRNA-related patents in China. The full name of "The Institute of Plant Protection" is "The Institute of Plant Protection, Chinese Academy of Agricultural Sciences".

Figure 5. Top 5 IPC cases for global siRNA-related patents.

Figure 6. Top 5 IPC cases for China siRNA-related patents.

Figure 7. RNAi drugs that have been launched globally related sequences, modifications, and delivery systems.

Figure 8. Roadmap for the technological development of delivery systems.

参考文献 10

[1]	Li, Q.; Chen, R.; Hu, P. Recent advances in pharmacokinetic characteristics and physiological pharmacokinetic modeling of small interfering RNA (siRNA) drugs. Acta Pharmaceutica Sinica. 2022, 57, 3146–3156.
[2]	Alshaer, W.; Zureigat, H.; Al Karaki, A.; Al-Kadash, A.; Gharaibeh, L.; Hatmal, M.M.; Aljabali, A.A.A.; Awidi, A. siRNA: Mechanism of action, challenges, and therapeutic approaches. Eur. J. Pharmacol. 2021, 905, 174178.
[3]	Zhu, L.F.; Wang, Z.J. A nalysis of Global Gene Therapy Drug Development Status. Prog. Pharm. Sci. 2022, 46, 325–338.
[4]	Guan, R.B.; Li, H.C.; Miao, X.X. Commercialization status and existing problems of RNA biopesticides. Scientia Agricultura Sinica. 2022, 55, 2949–2960.
[5]	John, M. Reflections on Alylam. Nat. Biotechnol. 2022, 40, 641–650.
[6]	Paunovska, K.; Loughrey, D.; Dahlman, J.E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 2022, 23, 265–280.
[7]	Ge, J.; Chen, L.F.; Nie, X.Y.; Chen, J. Analysis of patent development status of lipid nanoparticle delivery system form RNA vaccines. J. Chin. Pharm. Sci. 2023, 32, 112–121.
[8]	Zhang, L.; Liang, Y.Y.; Liang, G.H.; Tian, Z.L.; Zhang, Y.; Liu, Z.H.; Ji, X.Y. The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates. Front. Pharmacol. 2022, 13, 1090237.
[9]	Brown, C.R.; Gupta, S.; Qin, J.E.; Racie, T.; He, G.; Lentini, S.; Malone, R.; Yu, M.; Matsuda, S.; Shulga-Morskaya, S.; Nair, A.V.; Theile, C.S.; Schmidt, K.; Shahraz, A.; Goel, V.; Parmar, R.G.; Zlatev, I.; Schlegel, M.K.; Nair, J.K.; Jayaraman, M.; Manoharan, M.; Brown, D.; Maier, M.A.; Jadhav, V. Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates. Nucleic Acids Res. 2020, 48, 11827–11844.
[10]	Sun, B.; Lin, J.J.; Wang, S.S.; Sun, S.G. siRNAs and microRNAs are used for antiviral research progress. Chin. Med. Biotechnol. 2021, 16, 51–57.

RNA干扰药物专利分析

Innovative trends in RNA interference drugs: a comprehensive patent analysis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 8

参考文献 10

相关文章 7

编辑推荐

Metrics

本文评价

[1]	葛嘉, 陈龙飞, 聂小燕, 陈敬. mRNA疫苗脂质纳米颗粒递送系统的专利发展状况分析[J]. 中国药学(英文版), 2023, 32(2): 112-121.
[2]	李锴森, 王如东, 彭祎玮, 董达文, 齐宪荣. 核黄素修饰的脂质复合纳米粒共递送CXCR4 siRNA和阿霉素治疗高转移性癌症[J]. 中国药学(英文版), 2021, 30(3): 189-205.
[3]	闫仪, 崔仕贺, 孙晶, 李飘飘, 张海涛, 王坚成. 具有还原敏感可断裂的疏水尾链的新型阳离子脂质用于siRNA递送的研究[J]. 中国药学(英文版), 2018, 27(6): 383-396.
[4]	邱崇, 崔仕贺, 孙晶, 王坚成. 不同工艺制备的CLD/siRNA纳米粒体外性质差异性研究[J]. 中国药学(英文版), 2016, 25(9): 660-668.
[5]	邹朗, 黄野, 王晓锋, 马元, 刘洋, 关注, 张礼和, 杨振军. 3'-端肽缀合修饰提高寡核苷酸的血清稳定性[J]. 中国药学(英文版), 2014, 23(4): 215-219.
[6]	孟婷婷, 李井泉, 齐宪荣. 可共载基因与敏化剂用以增强多西他赛抗肿瘤效果的脂质纳米载药系统的制备与评价[J]. 中国药学(英文版), 2014, 23(3): 145-152.
[7]	李井泉, 仰浈臻, 孟婷婷, 齐宪荣. 肝癌靶向的阳离子脂质体共递送多西他赛和siRNA的研究[J]. 中国药学(英文版), 2014, 23(10): 667-673.